Across TCGA pan-cancer cohorts, GPRIN2 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated GPRIN2 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher GPRIN2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GPRIN2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
LIHC, HNSC, and DLBC are the cancer types where GPRIN2 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.